Data Foundry

Drug recalls 2026

Bisoprolol Fumarate and Hydrochlorothiazide tablets — Class II drug recall D-0301-2026

Ongoing recall by Unichem Pharmaceuticals USA Inc., reported 2026-02-11, distributed nationwide. cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.

Recall numberD-0301-2026
Product typeDrug
ClassificationClass II
StatusOngoing
Voluntary or mandatedVoluntary
Recalling firmUnichem Pharmaceuticals USA Inc., East Brunswick, NJ, United States
Recall initiated2026-01-21
Classified2026-01-30
Reported by FDA2026-02-11
DistributedNationwide (US)
Reason classescgmp, specification failure
NDC29300-0187, 29300-0187-01, 29300-0187-05, 29300-0187-10, 29300-0187-13, 29300-0188, 29300-0188-01, 29300-0188-05, 29300-0188-10, 29300-0188-13, 29300-0189, 29300-0189-01, 29300-0189-05, 29300-0189-10, 29300-0189-13
Lot numbersGBHL24005A
Expiration dates2026-09

Product

Bisoprolol Fumarate and Hydrochlorothiazide tablets, USP, 2.5 mg/6.25 mg, 100-count bottle, Rx Only, Manufactured by: UNICHEM LABORATORIS LTD., Pilerne Ind. Estate, Pilerne, Bardez, Goa 403 511, India, Manufactured for: UNICHEM PHARMACEUTICALS (USA), INC., East Brunswick, NJ 08816, NDC 29300-187-01

Reason for recall

cGMP Deviations: recall due to not meeting the N-Nitroso Bisoprolol impurity specification limits.

Machine access

This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0301-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.

Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.